More than 40 years ago Congress enacted the National Act to Wage War on Cancer. Since then little has changed to improve the outcomes for patients with pancreatic malignancy. During the same interval, improvements in care for patients with pancreatitis and the aftermath of pancreatitis have also lagged behind the successes seen in other acute and chronic diseases. It is time to chart a new course for pancreatic disease.
The Brenden-Colson Center for Pancreatic Care is a patient centric hub for clinical and research programs that focus on three main areas essential for alleviating suffering from pancreatic diseases: Early Detection, Advanced Therapy, and Quality of Life. The heart of the program is a close collaboration among five program leaders in a "center-without-walls" that connects clinical activities to laboratory research.
The Center is led by Co-Director Brett C. Sheppard, M.D., who directs the clinical programs and links his surgical care and clinical activities with the research programs, and Co-Director Rosalie C. Sears, Ph.D., who designs and oversees the basic science programs and collaborations. Stellar OHSU researchers Lisa M. Coussens, Ph.D., Emek Demir, Ph.D., Joe W. Gray, Ph.D, and Daniel L. Marks, M.D., Ph.D., along with oncologist Charles Lopez, M.D, Ph.D., lead team projects that advance the search for new detection methods, move promising new stand-alone and combination therapies into the clinical trials pipeline and search for novel therapies to enhance quality of life.
From this foundation, we continue to expand our network of collaborators, partners, and patients to enable us to make the leaps necessary to improve patient care.